Business

Lungpacer Medical Nominated for 2026 Prix Galien USA Award for Best Medical Technology

Financial Post · August 19, 2026 at 7:04 a.m.

Nomination by the Prix Galien Foundation recognizes the AeroPace® System, the first FDA-approved diaphragm neurostimulation therapy to help critically ill patients breathe on their own again EXTON, Pa., Aug.

19, 2026 (GL

Read the full article on Financial Post ›

5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on financialpost.com — the content belongs to Financial Post.

Lungpacer Medical Nominated for 2026 Prix Galien USA Award for Best Medical Technology

More from Financial Post

New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 2026

Snow Alert: It’s Snowing in Ikon Pass Country

William Watson: Let’s see the last draft. Inquiring voters want to know

Opinion: We need to reduce wildfire fuel and zone better

More in Business

New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 2026

Snow Alert: It’s Snowing in Ikon Pass Country

Old soup factory takes on new high-tech life as quantum computing firm gets $195M federal boost

William Watson: Let’s see the last draft. Inquiring voters want to know

Opinion: We need to reduce wildfire fuel and zone better

Zacatecas Silver Closes the Second Tranche of Non-Brokered Private Placement